66 pending office actions • 26 clients
| App # | Title | Client | Examiner | Art Unit | Status | Filed |
|---|---|---|---|---|---|---|
| 19339458 | Untitled | Viiv Healthcare UK (No.3) Limited | KASSA, TIGABU | 1619 | Non-Final OA | |
| 19210620 | PSMA ANTIBODIES AND USES THEREOF | Wuxi Biologics Ireland Limited | GEORGE, DENNIS CHERIAN | 1644 | Non-Final OA | May 16, 2025 |
| 19086720 | Antigen Binding Proteins | VIIV HEALTHCARE UK (No. 5) LIMITED | SZPERKA, MICHAEL EDWARD | 1641 | Non-Final OA | Mar 21, 2025 |
| 18721985 | Method for Preparing Outer Membrane Vesicles | Glaxosmithkline Biologicals SA | GRASER, JENNIFER E | 1645 | Non-Final OA | Jun 20, 2024 |
| 18702436 | Saponin Production | Glaxosmithkline Biologicals SA | CHATTERJEE, JAYANTA | 1662 | Non-Final OA | Apr 18, 2024 |
| 18613481 | METHODS OF TREATING AN IL-5 MEDIATED DISEASE BY ADMINISTERING AN IL-5 BINDING PROTEIN | Glaxosmithkline Intellectual Property Development Limited | HOWARD, ZACHARY C | 1674 | Non-Final OA | Mar 22, 2024 |
| 18686089 | Shigella Vaccine | Glaxosmithkline Biologicals SA | DUFFY, PATRICIA ANN | 1645 | Non-Final OA | Feb 23, 2024 |
| 18684923 | T7 RNA POLYMERASE VARIANTS FOR RNA SYNTHESIS | Glaxosmithkline Biologicals SA | PAK, YONG D | 1652 | Non-Final OA | Feb 20, 2024 |
| 18683531 | LOW-DOSE LYOPHILIZED RNA VACCINES AND METHODS FOR PREPARING AND USING THE SAME | Glaxosmithkline Biologicals SA | RONEY, CELESTE A | 1612 | Non-Final OA | Feb 14, 2024 |
| 18683520 | PREPARATION OF P2X3 ANTAGONIST | Glaxosmithkline Intellectual Property (No.3) Limited | YOUNGBLOOD, WILLIAM JUSTIN | 1629 | Non-Final OA | Feb 14, 2024 |
| 18402174 | BIOCONJUGATES MADE FROM RECOMBINANT N-GLYCOSYLATED PROTEINS FROM PROCARYOTIC CELLS | Glaxosmithkline Biologicals SA | JACKSON-TONGUE, LAKIA J | 1645 | Non-Final OA | Jan 02, 2024 |
| 18571386 | DAPRODUSTAT FOR REDUCING FATIGUE IN A SUBJECT WITH ANEMIA ASSOCIATED WITH CHRONIC KIDNEY DISEASE | Glaxosmithkline Intellectual Property (No.2) Limited | PATEL, SAGAR S | 1626 | Non-Final OA | Dec 18, 2023 |
| 18570926 | NOVEL MANUFACTURING METHOD OF DAPRODUSTAT AND PRECURSORS THEREOF | Glaxosmithkline Intellectual Property (No.2) Limited | HEASLEY, MEGHAN CHRISTINE | 1626 | Non-Final OA | Dec 15, 2023 |
| 18567687 | O-LINKED THIADIAZOLYL COMPOUNDS AS DNA POLYMERASE THETA INHIBITORS | Glaxosmithkline Intellectual Property (No.4) Limited | JARRELL, NOBLE E | 1699 | Non-Final OA | Dec 06, 2023 |
| 18567085 | COMBINATION TREATMENT OF CANCER WITH A PARP INHIBITOR AND A LIPOPHILIC STATIN | Tesaro, Inc. | SAEED, KAMAL A | 1626 | Non-Final OA | Dec 05, 2023 |
| 18552477 | ANTIGEN BINDING PROTEINS AND COMBINATIONS THEREOF | Glaxosmithkline Intellectual Property Development Limited | LANDSMAN, ROBERT S | 1647 | Non-Final OA | Sep 26, 2023 |
| 18283632 | IMMUNOGENIC COMPOSITIONS | The United States Department of Health and Human Services | PENNINGTON, HALLIE NICOLE | 1671 | Non-Final OA | Sep 22, 2023 |
| 18283601 | IMMUNOGENIC COMPOSITIONS | CUREVAC SE | CHEN, STACY BROWN | 1672 | Non-Final OA | Sep 22, 2023 |
| 18283516 | IMMUNOGENIC COMPOSITIONS | The United States Department of Health and Human Services | GRIZER, CASSANDRA SENN | 1672 | Non-Final OA | Sep 22, 2023 |
| 18547001 | Compounds Useful in HIV Treatment | VIIV HEALTHCARE COMPANY | KRISHNAN, GANAPATHY | 1693 | Non-Final OA | Aug 18, 2023 |
| 18366944 | NOVEL USE | Glaxosmithkline Intellectual Property Development Limited | RAO, SAVITHA M | 1691 | Non-Final OA | Aug 08, 2023 |
| 18262033 | Therapeutic Viral Vaccine | Glaxosmithkline Biologicals SA | LY, KRISTINA ELISABETH | 1671 | Non-Final OA | Jul 19, 2023 |
| 18262073 | Therapeutic Viral Vaccine | Glaxosmithkline Biologicals SA | CORNELIUS, CLAIRE ADRIENNE | 1672 | Non-Final OA | Jul 19, 2023 |
| 18269120 | SELF-AMPLIFYING MESSENGER RNA | Glaxosmithkline Biologicals SA | CORNELIUS, CLAIRE ADRIENNE | 1672 | Non-Final OA | Jun 22, 2023 |
| 18256989 | Chemical Compounds Useful for Inhibiting Nav1.8 Voltage-Gated Sodium Channels and Treating Nav1.8 Mediated Diseases | Glaxosmithkline Intellectual Property Development Limited | MCMILLIAN, KARA RENITA | 1623 | Non-Final OA | Jun 12, 2023 |
| 18332893 | DOSING REGIMEN | Halozyme, Inc. | PAGUIO FRISING, MICHELLE F | 1651 | Non-Final OA | Jun 12, 2023 |
| 18256982 | Nitrogen Containing 2,3-Dihydroquinazolinone Compounds as Nav1.8 Inhibitors | Glaxosmithkline Intellectual Property Development Limited | SEITZ, ANTHONY JOSEPH | 1629 | Non-Final OA | Jun 12, 2023 |
| 18330569 | Chemical Compounds | Glaxosmithkline Intellectual Property Development Limited | O DELL, DAVID K | 1621 | Non-Final OA | Jun 07, 2023 |
| 18255920 | COMBINATION THERAPY | VIIV HEALTHCARE COMPANY | YU, MISOOK | 1641 | Non-Final OA | Jun 05, 2023 |
| 18255442 | Novel Antigens | Glaxosmithkline Biologicals SA | SLOUP IV, RUDOLPH EDWARD | 1645 | Non-Final OA | Jun 01, 2023 |
| 18039604 | ANTI-TSLP ANTIBODY PHARMACEUTICAL COMPOSITION AND USE THEREOF | Shanghai Hengrui Pharmaceuticals Co., Ltd. | DONOGHUE, BRITTNEY ERIN | 1675 | Non-Final OA | May 31, 2023 |
| 18031899 | METHODS FOR TREATING CHOLESTATIC PRURITUS | Glaxosmithkline Intellectual Property (No.2) Limited | SZNAIDMAN, MARCOS L | 1628 | Non-Final OA | Apr 14, 2023 |
| 18131557 | IMMUNOGENIC COMPOSITION | Glaxosmithkline Biologicals SA | HINES, JANA A | 1645 | Final Rejection | Apr 06, 2023 |
| 18042485 | COMBINATION OF CABOTEGRAVIR AND LEVONORGESTREL | VIIV HEALTHCARE COMPANY | BURKETT, DANIEL JOHN | 1624 | Non-Final OA | Feb 22, 2023 |
| 18042314 | IMIDAZONAPHTHYRIDINES AND IMIDAZOPYRIDOPYRIMIDINES AS IFNAR2 AGONISTS FOR TREATING SARS-COV-2 INFECTIONS | Glaxosmithkline Intellectual Property Development Limited | AULAKH, CHARANJIT | 1621 | Non-Final OA | Feb 21, 2023 |
| 18010258 | HSV gE ANTIBODIES | Glaxosmithkline Biologicals SA | LANDSMAN, ROBERT S | 1647 | Non-Final OA | Dec 14, 2022 |
| 18010245 | FORMULATION COMPRISING DAPRODUSTAT | Glaxosmithkline Intellectual Property (No.2) Limited | TRAN, SUSAN T | 1615 | Non-Final OA | Dec 14, 2022 |
| 18001634 | Formulations | VIIV HEALTHCARE COMPANY | TRAN, SUSAN T | 1615 | Final Rejection | Dec 13, 2022 |
| 18001635 | Dispersible Tablet Formulations Comprising Dolutegravir | VIIV HEALTHCARE COMPANY | TRAN, SUSAN T | 1615 | Final Rejection | Dec 13, 2022 |
| 18001498 | MODIFIED EXOTOXIN A PROTEINS | Glaxosmithkline Biologicals SA | OGUNBIYI, OLUWATOSIN A | 1645 | Non-Final OA | Dec 12, 2022 |
| 18001551 | Shigella-Tetravalent (Shigella4V) Bioconjugate | Glaxosmithkline Biologicals SA | SHAHNAN SHAH, KHATOL S | 1645 | Non-Final OA | Dec 12, 2022 |
| 18008777 | BACTERIAL IMMUNIZATION USING NANOPARTICLE VACCINE | Glaxosmithkline Biologicals SA | SHAHNAN SHAH, KHATOL S | 1645 | Non-Final OA | Dec 07, 2022 |
| 18008771 | DOCK TAG SYSTEM | Glaxosmithkline Biologicals SA | COFFA, SERGIO | 1658 | Final Rejection | Dec 07, 2022 |
| 18008767 | GBS FERRITIN NANOPARTICLES | Glaxosmithkline Biologicals SA | SHAHNAN SHAH, KHATOL S | 1645 | Non-Final OA | Dec 07, 2022 |
| 18007931 | MODIFIED BETACORONAVIRUS SPIKE PROTEINS | Glaxosmithkline Biologicals SA | JADHAO, SAMADHAN JAISING | 1672 | Non-Final OA | Dec 02, 2022 |
| 18074268 | RNAI AGENTS FOR HEPATITIS B VIRUS INFECTION | Arrowhead Pharmaceuticals, Inc. | ANGELL, JON E | 1637 | Non-Final OA | Dec 02, 2022 |
| 17981673 | DRY POWDER INHALATION DRUG PRODUCTS EXHIBITING MOISTURE CONTROL PROPERTIES AND METHODS OF ADMINISTERING THE SAME | Glaxo Group Limited | LEE, WILLIAM Y | 1623 | Non-Final OA | Nov 07, 2022 |
| 17918654 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK (No. 5) LIMITED | SHIM, DAVID M. | 1626 | Non-Final OA | Oct 13, 2022 |
| 17918676 | SARS COV-2 SPIKE PROTEIN CONSTRUCT | Glaxosmithkline Biologicals SA | DIBRINO, MARIANNE | 1641 | Non-Final OA | Oct 13, 2022 |
| 17916916 | COMBINATION TREATMENT FOR CANCER BASED UPON AN ICOS ANTBODY AND A PD-L1 ANTIBODY TGF-BETS-RECEPTOR FUSION PROTEIN | Glaxosmithkline Intellectual Property Development Limited | EDGINGTONGIORDANO, FRANCESCA | 1643 | Non-Final OA | Oct 04, 2022 |
| 17913072 | ANTI-TN-MUC1 CHIMERIC ANTIGEN RECEPTORS | Glaxosmithkline Intellectual Property Development Limited | HECK, BRYAN WILLIAM | 1643 | Non-Final OA | Sep 20, 2022 |
| 17911712 | Compounds Useful in HIV Therapy | VIIV HEALTHCARE COMPANY | CREWS, JARET JAMES | 1691 | Final Rejection | Sep 15, 2022 |
| 17932200 | SELECTIVE P2X3 MODULATORS | Glaxosmithkline Intellectual Property (No.3) Limited | HEITMEIER, KENDALL NICOLE | 1621 | Final Rejection | Sep 14, 2022 |
| 17795312 | METHODS FOR IMPROVED CANCER TREATMENT | Cellphenomics GmbH | BAUSCH, SARAE L | 1699 | Non-Final OA | Jul 26, 2022 |
| 17854377 | PNEUMOCOCCAL CAPSULAR SACCHARIDE CONJUGATE VACCINE | Glaxosmithkline Biologicals SA | MORGAN, BAILEY MICHELLE | 1645 | Final Rejection | Jun 30, 2022 |
| 17790218 | NOVEL USE | 23Andme, Inc. | HENLEY III, RAYMOND J | 1629 | Non-Final OA | Jun 30, 2022 |
| 17661841 | ANTIBODIES DIRECTED AGAINST T CELL IMMUNOGLOBULIN AND MUCIN PROTEIN 3 (TIM-3) | AnaptysBio, Inc. | NATARAJAN, MEERA | 1643 | Non-Final OA | May 03, 2022 |
| 17763354 | IMMUNOGENIC COMPOSITIONS | Glaxosmithkline Biologicals SA | MORGAN, BAILEY MICHELLE | 1645 | Final Rejection | Mar 24, 2022 |
| 17632270 | PROCESS FOR PREPARING A COMPOSITION COMPRISING A PROTEIN D POLYPEPTIDE | Glaxosmithkline Biologicals SA | CHEONG, CHEOM-GIL | 1645 | Final Rejection | Feb 02, 2022 |
| 17588425 | VACCINE | Glaxosmithkline Biologicals SA | SHAHNAN SHAH, KHATOL S | 1645 | Non-Final OA | Jan 31, 2022 |
| 17628667 | QUANTIFICATION OF BIOCONJUGATE GLYCOSYLATION | Glaxosmithkline Biologicals SA | DUFFY, PATRICIA ANN | 1645 | Non-Final OA | Jan 20, 2022 |
| 17618283 | MUCOSAL VACCINE FORMULATIONS | Glaxosmithkline Biologicals SA | LI, BAO Q | 1671 | Non-Final OA | Dec 10, 2021 |
| 17617479 | 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS | Glaxosmithkline Intellectual Property Development Limited | ELENISTE, PIERRE PAUL | 1622 | Final Rejection | Dec 08, 2021 |
| 17600660 | GEPOTIDACIN FOR USE IN THE TREATMENT OF BACTERIAL URINARY TRACT INFECTIONS | Glaxosmithkline Intellectual Property Development Limited | BRAUN, MADELINE E | 1624 | Non-Final OA | Oct 01, 2021 |
| 17389599 | MODULATION OF HEPATITIS B VIRUS (HBV) EXPRESSION | Ionis Pharmaceuticals, Inc. | ARIETI, RUTH SOPHIA | 1635 | Final Rejection | Jul 30, 2021 |
| 17262098 | ANTIGEN PURIFICATION METHOD | Glaxosmithkline Biologicals SA | WANG, RUIXUE | 1672 | Final Rejection | Jan 21, 2021 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial